SEC Tracker
Get the app
SOLV · XBRL financial data

Solventum financial statements, every quarter

The same tables from 10 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (SOLV's year ends in late December)

In millions of dollarsMar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue2,0162,0812,0822,075*2,0702,1612,0961,998*2,0072,209
Gross profit1,1721,1371,165—1,1141,1751,135—1,0971,286
Research and development195192189199*193189183175*189178
Selling, general and administrative596701701784*769772780759*827927
Operating income (loss)381244275136*1522141,690124*81181
Other income (expense)(13)(34)(1)(16)*(11)(8)(5)(15)*(4)(9)
Income tax expense (benefit)92745(17)*(99)13248(5)*315
Net income (loss)2378912231*137901,26663*1392
Earnings per share, basic USD per share1.370.510.700.18*0.790.527.260.36*0.070.53
Earnings per share, diluted USD per share1.370.510.700.18*0.780.517.220.36*0.070.53
Weighted average shares, basic millions of shares173173173173*174174174174*174173
Weighted average shares, diluted millions of shares173174174175*175175175176*176173

Balance sheet

CSV

Fiscal quarters (SOLV's year ends in late December)

In millions of dollarsMar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents9968977727625344921,642878561403
Accounts receivable1,2201,0281,1051,0449261,0651,0191,0341,0591,310
Inventory9018999539658669621,0491,0661,0891,040
Total current assets3,3593,3633,3543,2493,0533,2084,4073,8593,5833,741
Property and equipment, net1,4911,5371,5991,6221,1981,3131,3361,326——
Right-of-use asset———176———214186188
Goodwill6,4686,4476,5926,3774,9915,2745,2605,7045,6265,626
Total assets14,71114,57814,74514,45714,52715,07413,97314,29414,09714,243
Accounts payable587495560618604643669687699701
Accrued liabilities—611450272356355464435337331
Commercial paper0000000000
Current portion of long-term debt00300200100000——
Total current liabilities1,8542,5712,9042,7032,5662,6202,9383,1363,3463,663
Long-term debt8,3038,3067,8097,8107,8137,8155,1375,0354,5754,573
Lease liability, non-current———86———142——
Total liabilities10,86011,71111,55311,49811,26511,4298,9879,2459,1289,443
Retained earnings—892112423784681,7341,7971,8101,902
Total stockholders' equity3,8512,8673,1922,9593,2623,6454,9865,0494,9694,800
Total liabilities and equity14,71114,57814,74514,45714,52715,07413,97314,29414,09714,243
Common shares outstanding (cover page) millions of shares173173173173173173173173173170

Cash flows

CSV

Fiscal quarters (SOLV's year ends in late December)

In millions of dollarsMar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)2378912231*137901,26663*1392
Stock-based compensation456*27*25*4934*41*37*5138*
Depreciation and amortization139133*133*150*129122*121*117*135133*
Net cash from operating activities442355*169*219*29169*76*95*(189)227*
Purchases of property and equipment10258*93*127*109110*97*63*8483*
Net cash from investing activities(102)(58)*(93)*(127)*(114)(110)*3,766*(745)*(77)(87)*
Share repurchases————00*——67288*
Net cash from financing activities462(396)*(202)*(104)*(139)(110)*(2,693)*(115)*(50)(300)*
Net change in cash802(99)*(125)*(10)*(223)(45)*1,148*(764)*(318)(157)*

Compare with peers

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
CompanyCash ($M)Revenue, quarter ($M)Operating cash flow, quarter ($M)Shares outstandingQuarter
Solventum4032,209227*170.2M 10-QJun 30, 2026
Medline2,3277,685715*not reported 10-QJun 27, 2026
Hologic2,1681,048230223.2M 10-QDec 27, 2025
Align Technology1,1031,056193*71.0M 10-QJun 30, 2026
West Pharmaceutical Services464875190*69.7M 10-QSep 30, 2026
Baxter International1,9752,976558*517.3M 10-QSep 30, 2026
Penumbra25441042*39.4M 10-QSep 30, 2026
Zimmer Biomet Holdings4102,177448*190.7M 10-QJun 30, 2026
Insulet53580288*69.4M 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.